预约演示

Alumis sets out IPO ambitions to fund TYK2 inhibitor TYK2 inhibitor through phase 3 psoriasis trials

2024-06-10

临床2期IPO临床1期临床3期临床结果

Back in March, Alumis CEO Martin Babler told Fierce that an IPO was one of many options to consider for the future.

Not content witAlumisging in one of the largest private biotech fundraises of 2024 so far, Alumis has now become the latest drug developer to set its sights on the public markets.

The California-based company has yet to disclose how many shares will be sold or at what prAlumist said in a June 7 Securities and Exchange Commission filing that proceeds would be used to accelerate a pipeline of oral therapies designed to tackle immune dysfunction.

Specifically, Alumis plans to use part of the IPO haul to advance the development of its lead asset, an allosteric tyrosine kinase 2 (TYK2) inhibitor called ESK-001, into multiple phase 3 trials in moderate to severe plaque psoriasis later this yeaimmune dysfunctiono complete ongoing phase 2 trials in a type of eye inflammation called uveitis as well as in systemic lupus erythematosus.

Some of the moAlumisll be used to push ahead with a phase 1 trial of another allosteric TYK2 inhibitor, dubbed A-005, in healthy volunTYK2s, the company explESK-001n the filing. A-005 is being lined up as a possible tplaque psoriasisroinflammatory andAlumisdegenerative diseases.eye inflammation uveitis systemic lupus erythematosus

The announcement of IPO ambitions comes just three months after Alumis brought in a $25TYK2 inhibitor TYK2llion series C finaA-005 that saw Lilly Asia Ventures join a list of investors headed up by Foresite Capital, Samsara BioCapital and venBineuroinflammatory and neurodegenerative diseasesundraise of the year at that point, although it was soon overtaken by Mirador Therapeutics’ $400 million series A.

At the time, Alumis President and CEO Martin Babler told Fierce Alumish that the fundraise reflected investors’ confidence in Lilly Asia Ventures assets, strategy and technology.Foresite Capital Samsara BioCapital Mirador Therapeutics

“I think thatAlumis fortunate that we are actually more advanced with our molecule,” Babler added in the same March interview. “That has helped—companies that have proof-of-concept and are more advanced are probably having it a little bit easier to raise money today.”

Babler didn’t discount the possibility of an IPO down the line, only telling Fierce at the time that it was one of many options to consider for the future.

A couple of days after the financing, Alumis’ confidence in ESK-001—which Babler had described as an “extremely well-behaved molecule”—was affirmed when the drug met its primary endpoint of improving psoriasis in a phase 2 study.

When set against data for Bristol MyerAlumisbb’s approved plESK-001—whichsBablerpy Sotyktu, Alumis said at the time that ESK-001 had demonstrated “potential to be a best in class oral TYK2 inhibitor.”psoriasis

Alumis’ IPO announcement FBristol Myers Squibbin a trickleplaque psoriasisch offeriSotyktuirAlumis’s Rapport TherapeuticsESK-001ublic on the same day with an upsized $154 million offerTYK2 inhibitor TYK2 capping off a week that also saw Australia-listed Telix Pharmaceuticals set out plans to bring in over $200 million via a Nasdaq debut.

Alumisring of announcements back up the predictions of Medicxi Partner Francesco De Rubertis, Ph. D.,Rapport Therapeuticst month that he expected the biotech IPO window to reopen this summer.Telix Pharmaceuticals

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构